Dual-agent molecular targeting of the ErbB2 receptor: killing one bird with two stones.

Full Abstract

No abstract is available for this article. See 'Journal and Publication Information' further down the page for details that may assist you in locating this article in electronic or hard copy media. The 'Related articles' section also further down the page, where available, may show links to abstracts of articles covering similar topics.

Learn Faster Today Improve your study skills

Author information

Author/s: Hirte, Hal W (HW); Hotte, Sebastien J (SJ);

Journal and publication information

Publication Type: Clinical Trial, Phase I; Comment; Editorial

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol), published in United States. (Language: eng)

Reference: 2008-Jul; vol 26 (issue 20) : pp 3301-2

Dates: Created 2008/07/09; Completed 2008/08/13;

PMID: 18490647, status: MEDLINE (last retrieval date: 11/6/2008)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

Comments and Corrections

CommentOn: J Clin Oncol. 2008 Jul 10;26(20):3317-23. (PMID: 18490651)

External Links for this article (including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Antibodies, Monoclonal - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Breast Neoplasms - drug therapy; genetics; pathology
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Delivery Systems
Female

Female
Humans
Prognosis
Quinazolines - administration & dosage
Receptor, erbB-2 - drug effects; genetics
Survival Analysis
Treatment Outcome

Associated Chemicals: Antibodies, Monoclonal (0) ; Quinazolines (0) ; lapatinib (0) ; trastuzumab (0) ; Receptor, erbB-2 (EC 2.7.1.112)

These are the highest related articles currently in the database:

See 100+ related articles.